Evidence map›Paper›PMID 31216218›Full record

Observational studyHuman vaccines & immunotherapeutics2019

Safety of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine when administered during pregnancy as part of the maternal immunization program in Brazil: a single center, observational, retrospective, cohort study.

Mauro Sancovski, Narcisa Mesaros, Yang Feng, M Angeles Ceregido, Dominique Luyts, Eliana De Barros

Registry-linked trialOpen access · hybridAbstract readObservational Study
In one paragraph

Observational study in Human vaccines & immunotherapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02757950 (A Post-marketing, Observational, Retrospective, Cohort Study to Assess the Safety of RefortrixTM), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02757950 completednot on this map

A Post-marketing, Observational, Retrospective, Cohort Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.

TypeobservationalSponsorGlaxoSmithKlineRan2016 to 2017Enrolled2,462ConditionsDiphtheriaArmsCombined diphtheria, tetanus and tricomponent acellular pertussis vaccine [Refortrix (Tdap)]
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Mauro SancovskiFaculdade de Medicina do ABC, Santo André, Brazil.
Narcisa MesarosGSK, Wavre, Belgium.
Yang FengNingyang Group Co., Limited, C/O GSK, Wavre, Belgium.
M Angeles CeregidoGSK, Wavre, Belgium.
Dominique LuytsGSK, Wavre, Belgium.ORCID 0000-0001-8195-1526
Eliana De BarrosGSK, Rio de Janeiro, Brazil.
GlaxoSmithKline (Belgium) · BEFaculdade de Medicina do ABC · BRGlaxoSmithKline (Brazil) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reduced antigen diphtheria-tetanus-acellular pertussis (Tdap) vaccination is included in the maternal immunization program in Brazil since September 2014. We investigated associations between maternal Tdap vaccination and pregnancy-related adverse events (AEs) (gestational diabetes, pregnancy-related hypertension, and pregnancy hemorrhage) and neonatal AEs of interest (preterm birth and small for gestational age). This descriptive, observational, retrospective, single-center study in Brazil (NCT02757950) compared data from medical charts of 1203 pregnant women who received Tdap as part of the maternal immunization program and delivered between May 2015 and February 2017 (exposed cohort) and 1259 unvaccinated women who delivered between September 2012 and August 2014 (unexposed cohort). Index dates were defined as the time of vaccination (27-39 gestational weeks; exposed cohort) or 27 gestational weeks (unexposed cohort). Cumulative incidences were calculated as the number of women with each event between index and delivery dates divided by the total number of women with vaccination date available in the exposed cohort (N = 1199) or the total number of women in the unexposed cohort (N = 1259). Cumulative incidences per 1000 persons were 8.34 versus 17.47 for gestational diabetes, 9.17 versus 24.62 for pregnancy-related hypertension, 3.34 versus 15.09 for pregnancy hemorrhage, 53.38 versus 96.11 for preterm birth, and 57.55 versus 49.25 for small for gestational age in the exposed versus unexposed cohorts. No increased risk of pregnancy-related AEs or neonatal AEs of interest was found following maternal vaccination with Tdap. These results should be interpreted cautiously due to limitations inherent to retrospective observational studies.

Indexed as

Immunization ProgramsAdolescentAdultAntigens, BacterialBrazilDiphtheriaDiphtheria-Tetanus-acellular Pertussis VaccinesFemaleHumansInfant, NewbornPregnancyPregnant PeopleRetrospective StudiesRisk FactorsTetanusWhooping CoughAntigens, BacterialDiphtheria-Tetanus-acellular Pertussis Vaccinesadverse eventmaternal vaccinationneonatePertussispregnancy

Identifiers

PMID31216218
PMCPMC6930109
OpenAlexW2949184654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.